Quantum BioPharma Submits Breakthrough MS Drug Candidate To UK's ILAP Program To Accelerate Patient Access

Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., the submission of its patented candidate breakthrough drug, Lucid-21-302 (Lucid-MS), to the Innovative Licensing and Access Pathway (ILAP) Passport program in the United Kingdom (UK). The ILAP Passport application was submitted for Lucid-21-302 as a new, first-in-class treatment for multiple sclerosis (MS).

The ILAP Passport is the first step in the UK's Innovative Licensing and Access Pathway (ILAP) – a program designed to accelerate the pace at which groundbreaking new medicines and treatments reach patients. ILAP brings together all key partners, including medicine developers, the Medicines and Healthcare Products Regulatory Agency (MHRA), health assessment bodies, the National Health System (NHS), and patients themselves. By working together through a single, streamlined platform, ILAP aims to reduce the time it takes to develop, review, approve, and deliver new treatments to patients. This highly coordinated and collaborative approach helps ensure that patients get the earliest possible access to the latest medical innovations, while also supporting the NHS and boosting the UK economy.